Seres therapeutics, inc. (MCRB)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
Cash flows from operating activities:
Net loss

-19,881

-18,778

-16,409

-10,759

-24,333

-21,287

-21,949

-27,787

-27,919

-28,953

-6,935

-28,018

-25,474

-25,276

-18,686

-27,913

-19,704

-19,634

-14,620

-12,555

-7,971

Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense

1,959

2,145

2,037

2,097

2,065

3,754

4,317

4,334

4,236

4,212

4,369

4,502

4,279

3,992

4,244

4,717

3,904

2,787

2,507

3,073

1,327

Depreciation and amortization expense

1,802

1,800

1,876

1,921

2,006

1,993

1,974

1,954

1,941

1,903

1,866

1,760

1,730

1,694

1,251

874

386

334

182

120

92

Non-cash operating lease cost

536

544

586

562

535

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accretion of discount on investments

66

-

-

-

-

15

67

82

50

50

50

57

59

-

-

-

-

-

-

-

-

Loss from revaluation of preferred stock warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

220

-213

Non-cash interest expense

314

-

-

-

-

-

-

-

-

0

1

-1

3

-

1

-53

54

98

128

111

30

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

-203

-485

-1,087

-2,328

643

595

1,085

1,211

-835

-251

507

-349

62

71

-192

1,679

1,040

-492

732

1,520

710

Accounts receivable

237

68

113

-5,063

6,667

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-6,634

189

-6,081

-11,420

-208

29,804

-8,465

-4,271

-3,592

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-3,015

-3,014

-3,015

-

-2,838

-2,907

117,290

-

-

-

-

Accounts payable

590

397

-212

829

-2,474

-459

1,643

-111

-1,426

1,646

1,149

-1,735

-1,916

3,497

-311

-936

1,331

2,150

673

48

-189

Operating lease liabilities

-1,066

-1,047

-1,085

-1,055

-1,024

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued expenses and other liabilities

-

-

-

-

-

-

-

-

-788

3,227

-488

558

-1,135

-1,839

4,875

2,797

-806

2,204

583

847

-706

Accrued expenses and other current and long-term liabilities

-1,771

-

109

-1,354

-1,650

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash (used in) operating activities

-24,251

-14,047

-18,292

-11,788

-32,393

12,666

-23,083

-25,674

-26,763

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from investing activities:
Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-25,649

-

-11,367

-25,322

101,415

-11,569

-11,279

-9,656

-8,340

Purchases of property and equipment

71

230

125

341

306

-196

478

702

953

685

464

1,280

2,247

5,687

5,859

6,546

3,400

1,236

1,477

1,435

214

Purchases of investments

12,931

-

-

-

-

0

6,376

10,186

5,270

22,206

31,933

21,282

22,513

44,866

39,194

161,233

45,301

70,661

132,850

4,995

59,255

Sales and maturities of investments

22,439

-

-

-

-

17,200

27,392

47,238

44,257

32,187

48,318

40,056

37,751

70,264

50,895

58,910

66,425

-

-

-

-

Net cash (used in) provided by investing activities

9,437

4,653

-34,524

-341

-306

17,396

20,538

36,350

38,034

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from financing activities:
Proceeds from exercise of stock options

60

0

25

0

120

11

40

64

32

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock and restricted common stock

120

23

0

0

153

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from at the market equity offering, net of commissions

4,116

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Changes in restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-118

0

1

-

-

-

-

Net cash provided by investing activities

-

-

-

-

-

-

-

-

-

-

-

-

12,991

-

5,960

-108,869

17,723

15,798

-95,757

2,295

-59,469

Proceeds from issuance of convertible preferred stock, net of issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-24

Proceeds from exercise of stock options and common stock warrants

-

-

-

-

-

-

-

-

-

-

-

-

19

-

-

-

157

2

165

6

89

Payments for repurchase of common stock for employee tax withholdings

-

-

-

-

-

1

-1

0

197

-

-

-

-

-

-

-

-

-

-

-

-

Issuance of common stock under ESPP plan

249

0

89

0

207

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

4,545

25,110

-118

60,759

480

45

298

90

-165

-

-

-

-

-

-

-

-

-

-

-

-

Net increase (decrease) in cash and cash equivalents

-10,269

15,716

-52,934

48,630

-32,219

30,107

-2,247

10,766

11,106

-

-

-

-

-

-

-

-

-

-

-

-

Repayment of notes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

2,000

300

300

Payments of initial public offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

780

1,052

1,096

Net cash (used in) provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

19

-

1,194

787

157

2

140,400

-1,346

-1,331

Net increase (decrease) in cash, cash equivalents and restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-12,639

-

-

-

-

-

-

-

-

Net increase (decrease) in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-4,213

-133,404

119,295

4,231

33,364

-8,707

-69,140

Supplemental disclosure of cash flow information:
Cash paid for interest

610

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash paid for interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1

98

10

1

87

35

40

Supplemental disclosure of non-cash investing and financing activities:
Unsettled issuance of common stock from the at the market offering

62

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred offering costs included in accounts payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

618

162

Property and equipment purchases included in accounts payable and accrued expenses

133

8

-34

-46

134

-85

152

-303

393

424

313

-209

349

-2,834

-415

1,504

3,395

2,305

-70

690

28